OpenAI Rejects Apple Trade Secret Theft Claims 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
France Targets Shein, Temu With Fast-Fashion Fees 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Add as a preferred source on Google
YAVNE, Israel, March 08, 2018 -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will present a corporate overview at the Cowen & Company 38th Annual Health Care Conference and the Oppenheimer & Co 28th Annual Healthcare Conference.
| Cowen & Company 38th Annual Health Care Conference | |
| Date: | Wednesday, March 14 |
| Time: | 9:20 am Eastern Time |
| Location: | Boston Marriott Copley Place, Vineyard Ballroom, 4th Floor |
| Oppenheimer & Co. 28th Annual Healthcare Conference | |
| Date: | Tuesday, March 20 |
| Time: | 2:45 pm Eastern Time |
| Location: | Westin New York Grand Central, Track 61 |
About MediWound Ltd.
MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid®, received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe and Israel and Argentina. NexoBrid® represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues.
MediWound's second innovative product, EscharEx® is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx® contains the same proteolytic enzyme technology as NexoBrid®, and benefits from the wealth of existing development data on NexoBrid®. In two Phase 2 studies, EscharEx® has demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications. For more information, please visit www.mediwound.com.
Contacts:
Sharon Malka
Chief Financial and Operations Officer
MediWound
[email protected]
Bob Yedid
Managing Director
LifeSci Advisors, LLC
[email protected]
